OS yet to reach a median at 8 years and a PFS of 44 months, significantly better than non IFN high-dose A single centre series of 195 consecutive newly diagpatients (P Ͻ 0.0036). However, although we showed nosed untreated myeloma patients under 70 years, seen benefit for selected patients in studies and trials between September 1986 and March 1994, were ana-(particularly with IFN) during the 8-year period of the lysed to assess the impact of current intensive treatment series, this did not translate into overall PFS benefit in methods upon remission rate, response rate and subour study for unselected cohorts of patients for 1986-sequent outcome. They were predominantly an unselec-1988 (64 patients) 1989-1992 (100 patients) and 1992-ted population based group of patients (other than by 1994 (31 patients) in spite of progressive increases in age) that could be used by purchasers of health care the proportion of patients receiving IFN (respectively 6, as a model for outcome assessment. All patients were 35 and 58%). This is likely to be due to the dilution scheduled to receive a care plan which included a of benefit to specific patients by the overall number of sequential package of treatment consisting initially of patients involved. Outcome data from unselected courses of infusional chemotherapy using vincristine, patients are now expected by purchasers and presented adriamycin and methyl prednisolone (VAMP) and 90 of in this way, help qualify the activity impact of advances these also received cyclophosphamide (C-VAMP).
new methods of treatment for cohorts of unselected patients
Patients and methods in the context of the market place.
We report here on a 10-year experience in a single centre Between September 1986 and March 1994, 195 consecutive new untreated myeloma patients were seen at the Royal to see if we can gain a greater perspective on the applicability of a treatment strategy to a population of myeloma Marsden Hospital, and Table 1 shows the demographic distribution of age, sex, stage, beta 2 microglobulin and creatipatients at large. It is argued that such single centre studies are highly selective, but large multi-institutional randomnine at presentation. The distribution of these parameters is also shown in Table 2 for the 141 of these patients who ised clinical trials are also highly selected -recruitment to the MRC myeloma VII Trial for the 2-year period from received high-dose treatment (melphalan or busulfan), including the 112 (57%) who specifically received highOctober 1994 to October 1996 from the North and South Thames Region (population 13.9 million) accrued only 20 dose melphalan plus an autograft. Table 2 compares the demography of our patients with those reported by the new untreated patients (personal communication, MRC) under the age of 65 years, which corresponded to only 5.5%
French Registry 10 and the Mayo Clinic group. 11 We have also included patient details on the MRC VII trial which is of potential patients filling the entry criteria for the trial over the same period of time.
an ongoing study (personal communication). This paper includes the results of all previously untreated patients under 70 years seen in the Myeloma Unit at our Induction treatment Hospital between September 1986 and March 1994. A large number of these patients are population base referrals from VAMP: Sixty-seven patients received courses of VAMP 3 (vincristine 0.4 mg i.v. by continuous infusion over 24 h × general practitioners and district general hospitals. The patients studied were under 70 years of age, but this was 4 days, doxorubicin 9 mg/m 2 ), i.v. by continuous infusion over 24 h × 4 days and methyl prednisolone 1.5 g i.v. or only because older patients were not usually referred because of our known age cut-off policy. (However, seven p.o. × 4 days and then tapered) as initial treatment following diagnosis. patients over 70 years seen during this period were not included in the analysis.) We realise that a specialist cancer centre, (with a regional radiotherapy commitment) may C-VAMP: Ninety patients received courses of VAMP chemotherapy plus weekly cyclophosphamide 500 mg i.v. have a bias towards specific myeloma problems at presentation, such as cord compression and pathological fractures, on days 1, 8 and 15 of the cycle. 3 but our centre is in the middle of a very dense population area and our recruitment of primary and secondary patient V-C-VAMP: Thirty-eight patients received courses of C-VAMP plus verapamil in an attempt to overcome drug referrals in the local vicinity was twice as high as the corresponding recruitment rate for the MRC trial.
resistance. 12 Verapamil was given i.v., 10 mg in 10 ml of All patients in the study were planned to receive a sequence of treatments which included a protocol of C-VAMP (V-C-VAMP), and subsequently the post-C- an unselected patient population.
Intensive treatment for previously untreated myeloma R Powles et al 437 Table 2 Comparative demography from four centres normal saline as a continuous infusion over 24 h via a syrMaintenance interferon inge driver starting 4 h before the VAMP infusion and finAfter high-dose treatment, patients were started on mainteishing 4 h after. The initial C-VAMP patients (n = 46) and nance interferon alpha (3 megaunits/m 2 three times a week the V-C-VAMP patients were a part of a randomised trial.
s.c. Schering Plough, New Jersey, USA) since July 1977 All courses in these three programmes were repeated initially as part of a randomised trial, 8,9 and subsequently, every 21 days until plateau response occurred (see below)
in all patients when the WBC count reached 2 × 10 9 /l and or the patients went into complete remission (CR). One platelet count 50 × 10 9 /l. The dose of interferon was further course was then given.
reduced or stopped according to haematological criteria or other toxic manifestations.
High-dose treatment
Response and relapse criteria Patients were planned to receive high-dose treatment and an autograft rescue with bone marrow 6, 13 or peripheral Our response criteria and definition of complete remission blood stem cells 9 6 weeks after the last chemotherapy cycle. have been described earlier. 6 Four criteria had to be met Treatment comprised melphalan (200 mg/m 2 ) on day −1 if for a patient to be regarded as having achieved complete the EDTA clearance was Ͼ40 ml/min. A reduced dose of remission (CR): (1) no paraprotein measurable by scanning melphalan (100 mg/m 2 ) was used if EDTA was between densitometry of serum proteins separated on cellulose acet-30-40 ml/min. In patients with Ͼ20% marrow infiltration, ate membrane by electrophoresis and stained with Ponceau melphalan 140 mg/m 2 without rescue was used. Adequate S; (2) no detectable Bence-Jones proteinuria on electrohydration pre-and post-high-dose melphalan was ensured phoresis of neat urine stained with colloidal gold; (3) 5% or to maintain a urine output of 20 ml/min 1 h post-high-dose, fewer plasma cells of normal morphology on bone marrow and 500 ml/hr in the subsequent 2 h. Busulfan was used as aspiration; and (4) criteria 1-3 had to be fulfilled for at conditioning in patients with poor renal function. A total least 3 months. Patients were regarded as having achieved dose of 16 mg/kg was used given at a dose of 1 mg/kg 6 a partial response (PR) if there was a 50% decrease in hourly p.o. × 4 days. Until November 1992, all patients measurable paraprotein (IgG or IgA myeloma) or bone received an autologous bone marrow transplant (ABMT).
marrow infiltration (non-secretory or Bence-Jones Marrow was harvested approximately 6 weeks after commyeloma) which was sustained for a month or more. pletion of chemotherapy. The target mononuclear cell colRelapse was defined as reappearance of paraprotein, or lection was 2-5 × 10 8 cells/kg of body weight. Subbone marrow infiltration of more than 5% for patients in sequently, peripheral blood stem cell transplants (PBSCT) CR, and a 25% increase in measurable paraprotein on two were used with G-CSF mobilisation. Six weeks after the samples 1 month apart for patients in PR. No response (NR) last chemotherapy cycle, home administration of s.c. Rh Gwas considered if the patient failed to achieve a CR or a PR. CSF (Amgen, Thousand Oaks, CA, USA) was started at a dose of 125 gm/m 2 12 hourly for 7 days (14 doses).
Informed consent Leukapheresis was performed on 4 consecutive days, starting on day 5 (days 5-8), using the Cobe separator (Cobe, Patients entering trials, or being treated with standard inDenver, CO, USA). The median cell dose returned to the house care plans all consented according to Royal Marsden ABMT patients was 2.04 × 10 8 cells /kg and the median Trust Ethical Committee criteria. cell dose returned to the PBSCT patients was 7.07 × 10 8 cells/kg.
Statistical considerations Patients were admitted on the day of conditioning and transplants were usually undertaken in a four-bedded ward Patient characteristics were compared using the 2 test with the Yates correction. The duration of response was measwithout barrier nursing.
438 Table 3 Response at end of induction (VAMP/C-VAMP/V-C-VAMP) ured either from the date of start of induction treatment or from high-dose treatment (see below Kruskal-Wallis test. Table 4 High-dose treatment (n = 141) Table 2 shows that our series does not represent a highly selected group of patients when compared with two 
Population-based demography

Induction chemotherapy
All 195 patients were able to start initial cytoreductive infusional chemotherapy, and they received VAMP (67), C-VAMP (90) or verapamil + C-VAMP (38), with a ipheral blood stem cells). Table 1 shows that older patients, as well as those with poor renal function, were significantly more likely to belong to the group which did not ultimately receive HDM plus autologous rescue. Of the 54 patients who did not receive high-dose treatment, 17 died during CR rate in the selected group of 112 patients who went on the induction period (of which eight deaths were treatmentto receive HDM plus an ABMT or PBSCT is 74.1%. related), and the remaining 37 had a poor performance Details of responses are also shown in Table 5 . There was status following induction, or refused the treatment. a total of seven (4.9%) treatment-related deaths in the Table 2 depicts a comparative analysis of our patient patients who had received high-dose treatment, of which group with those of other centres. We have a higher profive occurred in the 23 patients who received melphalan portion of patients with a beta 2 microglobulin of у3 mg/l alone, one death occurred in a patient who had received (64 vs 47.5; P = 0.014) compared to the French registry high-dose busulphan and PBSCT and one more in a patient data. Similarly, we have more stage III patients (78.9 vs who received melphalan plus ABMT. 34%) compared to the Mayo Clinic group.
Thus, the procedure-related mortality of high-dose melphalan and rescue is less than 1%. All seven deaths were related to infection, with one patient dying of Aspergillus Response pneumonia and another of disseminated Aspergillosis. The outcome of the induction infusional chemotherapy for all 195 patients is shown in Table 3 with a complete
Haematological recovery remission (CR) rate at the end of induction of 18%. The high-dose treatment schedule and when it was received by As expected, recovery of both neutrophils and platelets was significantly faster (P Ͻ 0.05) in the group of 112 patients the patients is shown in Table 4 . Table 5 shows the overall CR rate in the whole group as 52.8% (103/195). The final who received HDM plus autologous rescue vs the 29 439 Table 6 Haematological recovery (n = 141) (median days to engraftment) curves are plotted from the start of induction treatment. When plotting the PFS curves in all patients (n = 195) the first progression has been considered which might in some patients be before high-dose therapy and subsequently the patients may have achieved a CR following high-dose treatment. On comparing (from high-dose treatment) the OS and the PFS in patients who received some form of high-dose treatment against those who received high-dose melphalan plus an autograft, the latter fared significantly better ( Figures 3 and 4) . Thus, the 112 patients who received compared to 13.2 months (P Ͻ 0.005) and the median overall survival has just been reached at 6.6 years compared with 2.6 years (P Ͻ 0.005). The survival curves plotted in all these high-dose patients measures response from the patients who received melphalan alone (n = 23) or busultime of high-dose. phan plus rescue (n = 6) ( Table 6 ).
Maintenance interferon Survival and relapse
A total of 57 patients have gone on to receive maintenance The actuarial OS from start of treatment of the 195 patients interferon, and 84 have not, subsequent to consolidation is a median of 4.5 years from first treatment and at 9 years with high-dose treatment. The median PFS in the interferon it is 29% (Figure 1 ). The median progression-free survival group is 44 months, as against 21 months in the non-inter-(PFS) for the whole group is 25 months (Figure 2 ). These 71 patients entered the interferon trial. The total in either or both studies was 96 patients.
Response to refractory disease
Of the 39 refractory myeloma patients included in this study (Table 3) only nine did not receive high-dose treatment. Of the 30 who received high-dose treatment, 15 had HDM and a graft, and 15 had other high-dose treatment. Thirteen subsequently attained CR, six a PR, six had no response and five died following high-dose treatment. Partial response to conventional initial chemotherapy and 50% with median overall survivals of about 30 months. [16] [17] [18] [19] The introduction of infusional chemotherapy [1] [2] [3] and myeloablative 6,7 treatment has, however, resulted in significant CR rates 6,7,9,10,13,20-22 mimicking those seen for acute leukaemias in the 1970s. In previous reports from our feron arm; Figure 5 shows this group of patients fared siggroup we have focussed mainly on an analysis of a selected nificantly better than the group which did not receive intergroup of patients who received HDM plus an ABMT, 13 and feron. This was not however a randomised comparison.
Discussion
a randomised controlled trial of IFN versus no treatment Table 7 has divided the study period into three groups after high-dose treatment. 8, 9 Not all patients in these two where important changes in clinical practice took place.
reports are included in this currently reported series because Comparing the median PFS of the three time periods these studies included patients who had had treatment elsedescribed, there was no significant difference ( Figure 6 ).
where before coming to the Marsden. There were also new IFN was significantly beneficial for prolonging PFS in patients treated during the study period at the Marsden who patients randomised during the 3.5 years of our IFN trial did not enter these trials. This present paper includes non-(July 1988-November 1991) 8,9 but no impact could be seen trial patients and is confined to all previously untreated during this period on median PFS of all unselected patients patients seen at our hospital between 1986 and 1994. The (including the IFN patients) because the total number of purpose of the paper was to examine the impact of these patients who have received IFN in this paper is still too trials on our overall practice. small (n = 57).
We feel our myeloma practice of new untreated referrals represents a predominantly unselected population-based Recruitment into formal trials group of patients, with the obvious proviso of selection due to age because we have an age cut-off policy of not taking Eighty-five out of a potential 100 concurrent patients were patients over 70 years. We are mindful of our status as a recruited into the randomised verapamil trial and 46 out of specialist cancer hospital which may also bias referral, for example those requiring additional radiotherapy for cord compression or pathological fractures at presentation. We are also sent patients with either logistic, psychological or diagnostic problems that preclude initial infusional chemotherapy. We have identified 12 such patients who were under 70 years of age referred during the study period and not included in this study; six remain alive and the median survival has not been reached at 43 months. This long median survival allowed us to reasonably not include their data in the overall analysis because of the heterogeneity of their management and because they would not materially affect the conclusions. Thus the components of treatment offered at the Royal Marsden since 1986 are infusional chemotherapy, highdose treatment and maintenance interferon. Each of these components have shown benefit in selected studies 1, [3] [4] [5] [6] 8, 9, 13 and collectively they have dramatically improved the outlook for selected patients with myeloma. With infusional VAMP programme has raised the CR rate from 8 to 24%
Intensive treatment for previously untreated myeloma R Powles et al 441 Table 7 Study period divided into three groups when significant changes in clinical practice occurred after a median of five courses of treatment. 3 The introducall benefit for PFS for the much larger denomination of patients that represented the source of selection for those tion of high-dose treatment has significantly improved complete remission rate. In this present report, our own experiwho received IFN. Thus, although the median survival for our whole group of patients is 4.5 years which is superior ence shows an overall CR rate of 53% in the total group of patients, but this is due predominantly to the very high to that seen with conventional chemotherapy, [16] [17] [18] [19] the median PFS (complete remissions and partial responders) response with a CR rate of 74% in the group who received high-dose melphalan plus an autograft. Therefore, highremains at a little over 2 years, even in the group of patients who received high-dose melphalan and an autograft. This is dose treatment has proved advantageous in terms of achieving high CR rates, and we have previously reported that similar to most other groups using high-dose treatment.
20-24
Attal et al 25 have recently published the results of a prothis correlates with significant benefit in terms of quality of life. 5 However, planned treatment was not complete; spective randomised trial comparing autologous bone marrow transplantation and chemotherapy, and the probability only 72.3% were able to receive high-dose treatment and only 57.4% HDM plus autologous rescue.
of event-free survival for the high-dose group was 28% at 5 years with an overall survival of 52%. When we devised this high-dose programme, current opinion was that melphalan was cleared by the kidneys, and
In spite of all these measures, patients with myeloma, even in CR show molecular evidence of continuing disease our protocol incorporated the alternative of busulphan for those patients with poor renal function. Recent data from and ultimately relapse. Different treatment approaches including double autologous transplants have been used, 24 Arkansas 23 suggests that this precaution is no longer required.
but besides improving on the complete remission rates, very little evidence exists as to whether this approach will Concerning the use of melphalan alone without marrow rescue, the treatment-related mortality in this group of impact upon survival. Allogeneic transplantation has not gained much popupatients was very high (22%). It represents the group of patients in whom it is not possible to obtain a marrow harlarity, mainly because of the age group of the patients involved and the high procedure-related mortality associavest due to excessive involvement of the marrow with plasma cells. We have been impressed by the observation ted with allografts.
Results from the EBMT registry, 26 as well as those from that no patient has required the use of melphalan alone, without rescue, since the introduction of peripheral blood Cavo's group, 27, 28 suggest that patients with responsive disease as well as those with less prior treatment have a better stem cell rescue.
The use of interferon in this programme was more recent; outcome as against those who have received more prior treatment. Therefore, it might be worthwhile offering this it occurred during the course of the study when results from the randomised interferon trial showed a significant option of treatment to young, fit, newly diagnosed myeloma patients with a matched donor, and this is our current improvement in outcome for IFN when compared with no treatment. 8, 9 We were therefore disappointed not to see an approach to patients aged less than 55 years. However, no patients in this series of 195 patients received an allograft, impact of our interferon trial on the outcome of patients in the whole practice after its introduction into our routine so the overall place for allografting in our sequential package for untreated patients is, at present, small. For the vast clinical use, but the marked beneficial results seen in the controlled trial were diluted out by the larger number of majority, however, who undergo an autograft and obtain CR, it is now crucial that treatment methods are identified patients not selected for the treatment. However, we were reassured when we subsequently analysed data on the which prolong these remissions, and perhaps identify subgroups that can be cured. whole series to find that all patients who did receive interferon had significantly superior PFSs than those who did Obviously, further multicentre controlled trials are also required for existing treatment methods with all the known not, mimicking the results of the randomised trial on a predominantly different group of patients. Clearly, for selected advantages of such methodology. The current MRC Myeloma VII trial comparing ABCM with C-VAMP and autopatients IFN is beneficial, (and thus important information for the health care purchasers of myeloma treatment for grafting with IFN is just such a trial, but this will only be meaningful if interpreted in terms of the total denominator specific patients), although we still could not see any over- when health care purchasers want to buy the best care for
